FDA Approves Upadacitinib (Rinvoq), New JAK Inhibitor for RA

Share this post

Upadacitinib is for adults with moderately to severely active rheumatoid arthritis who fail to respond adequately or are intolerant to methotrexate.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply